PTC Therapeutics makes series of changes
pharmafile | January 27, 2014 | Appointment | Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing |Â Â PTC TherapeuticsÂ
Biopharma firm PTC Therapeutics has expanded its senior management team with a raft of appointments.
Robert Spiegel (pictured) becomes its chief medical officer and Murad Husain vice president, Global Regulatory Affairs.
PTC has also announced the promotions of Joseph Colacino to senior VP, Drug Discovery, and Ernest Dietel to senior VP, Quality.
In addition, Jay Barth who is their senior VP of Clinical Development is leaving the firm to pursue other opportunities.
In 2011 Spiegel joined PTC on a part-time consulting basis as chief medical officer. In his new role he will be responsible for all aspects of clinical development, and prior to joining the firm he conducted the same role at Schering-Plough.
Husain brings to PTC more than 25 years of pharma industry experience, with 20 years in regulatory affairs. Prior to joining the firm Husain was the VP of this area at Savient Pharmaceuticals.
He has led numerous worldwide regulatory teams for drug and biologics development and registration while at Pfizer, Hoffman-La Roche, Serono, AstraZeneca and Forest Laboratories.
Dr Colacino joined PTC in March 2003 as VP of Drug Discovery. Colacino joined PTC after 14 years at Eli Lilly and Company, where he held positions as research acquisition advisor, director of virology, and head of biology for infectious diseases research.
Dietel joined the company in 2009 and became VP of Quality Assurance in 2012. From 2005 to 2009, he served as president of DRE Enterprises, a consulting company that provided services to the pharmaceutical industry in areas of quality, manufacturing, validation, regulatory and business development.
Related Content
Roche’s Evrysdi drug for SMA shown to significantly increase survival
Roche’s Evrysdi therapy for the treatment of children with type 1 spinal muscular atrophy (SMA) …
Roche’s SMA treatment Evrysdi approved by European Commission
The European Commission has granted marketing authorisation to Roche and PTC Therapeutics’ Evrysdi, for the …
Roche and PTC’s SMA treatment shows positive trial results
Roche and PTC Therapeutics’s Evrysdi treatment for children and adults with Type 2 or Type …
